New compound may halt drug-resistant lung cancer
December 24th, 2009
The ability to make, test, and map the atomic structure of new anti-cancer agents has enabled a team of Dana-Farber Cancer Institute scientists to discover a compound capable of halting a common type of drug-resistant lung cancer.
In a study to be published in the December 24/31 issue of the journal Nature, the researchers report that non-small cell lung cancers that had become invulnerable to the drugs Iressa- and Tarceva- were stymied by a compound designed and formulated in a Dana-Farber lab.